China's genome editing startup EdiGene nets $62m in Series B+ round

China's genome editing startup EdiGene nets $62m in Series B+ round

Photo: Pixabay

Chinese genome editing startup EdiGene Inc has secured 400 million yuan ($61.7 million) in a Series B+ round of financing led by private equity (PE) firm Loyal Valley Capital to advance its pipeline into clinics and to scale up the business operation.